GLP-1 competition persists: Lilly beats estimates, Novo falls shortAnother quarter, another battle on the GLP-1 front. This time, the winner seems to be Eli Lilly and Co., which reported a 48% increase in second-quarter sales driven primarily by tirzepatide drugs Zepbound and Mounjaro for diabetes and obesity drugs, blowing past analyst expectations. Though also disclosing impressive numbers, Novo Nordisk A/S found investors focusing on sales of its pill version of Wegovy (semaglutide), which fell short of analyst estimates for the three months ending June 30.